作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
摘要: 本文报道一例肺、肾受累的抗中性粒细胞胞浆抗体(antineutrophil cytoplasmic antibodies, ANCA)相关性血管炎患者, 给予经典的糖皮质激素、环磷酰胺、血浆置换诱导缓解治疗有效。该患者在使用硫唑嘌呤维持治疗期间共出现2次感染, 后换用超小剂量(100 mg/次)利妥昔单抗维持治疗病情稳定。个体化利妥昔单抗治疗ANCA相关性血管炎效果显著, 同时避免了过度免疫抑制, 减轻了患者的经济负担。本例患者的诊疗经验有助于提高临床医生在ANCA相关性血管炎维持治疗方面的认识。
-
关键词:
- 抗中性粒细胞胞浆抗体相关性血管炎 /
- 利妥昔单抗 /
- 硫唑嘌呤
Abstract: We reported a case of ANCA-associated vasculitis with pulmonary and renal involvement that was effectively treated with glucocorticoids, cyclophosphamide, and plasma exchange therapy. The patient suffered two infections during maintenance treatment with azathioprine and was later switched to ultralow-dose (100 mg) rituximab to keep the disease in remission. Individualized rituximab therapy is effective in treating ANCA-associated vasculitis, while avoiding excessive immunosuppression, and reducing the financial burden. The diagnosis and treatment of this patient may help clinicians improve their understanding of maintenance therapy for ANCA-associated vasculitis.作者贡献：吴海婷负责收集临床资料、撰写论文；李航负责指导论文写作。利益冲突：所有作者均声明不存在利益冲突注：本研究发表已获得患者知情同意。 -
[1] Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis[J]. Arthritis Rheumatol, 2022, 74: 400-406. doi: 10.1002/art.41983 [2] Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis[J]. J Am Soc Nephrol, 2010, 21: 1628-1636. doi: 10.1681/ASN.2010050477 [3] Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases[J]. Kidney Int, 2021, 100: 753-779. doi: 10.1016/j.kint.2021.05.015 [4] Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis[J]. N Engl J Med, 2010, 363: 221-232. doi: 10.1056/NEJMoa0909905 [5] Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis (RITUXVAS)[J]. N Engl J Med, 2010, 363: 211-220. doi: 10.1056/NEJMoa0909169 [6] Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis[J]. N Engl J Med, 2014, 371: 1771-1780. doi: 10.1056/NEJMoa1404231 [7] Sanderson J, Ansari A, Marinaki T, et al. Thiopurine methyltransferase: should it be measured before commencing thiopur-ine drug therapy[J]. Ann Clin Biochem, 2004, 41: 294-302. doi: 10.1258/0004563041201455 [8] Tieu J, Smith R, Basu N. et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines[J]. Rheumatology (Oxford), 2020, 59: e24-e32. doi: 10.1093/rheumatology/kez640 [9] Goel R, Morgan M, Chanouzas D, et al. Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis[J]. Rheumatol Adv Pract, 2021, 5: rkab039. doi: 10.1093/rap/rkab039 [10] Moiseev SV, Bulanov NM, Zykova AS, et al. Rituximab in ANCA-associated vasculitis: fewer infusions or ultra low-dose maintenance therapy[J]. Ann Rheum Dis, 2019, 78: e99. doi: 10.1136/annrheumdis-2018-213873 [11] Schoergenhofer C, Schwameis M, Firbas C, et al. Single, very low rituximab doses in healthy volunteers—a pilot and a randomized trial: implications for dosing and biosimilarity testing[J]. Sci Rep, 2018, 9: 124. [12] Charles P, Terrier B, Perrodeau E, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase Ⅲ trial (MAINRITSAN2)[J]. Ann Rheum Dis, 2018, 77: 1143-1149. doi: 10.1136/annrheumdis-2017-212878 [13] Van Dam LS, Oskam JM, Kamerling SWA, et al. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients[J]. Front Immunol, 2020, 11: 566732. doi: 10.3389/fimmu.2020.566732 [14] Charles P, Perrodeau É, Samson M, et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial[J]. Ann Intern Med, 2020, 173: 179-187. doi: 10.7326/M19-3827 [15] Merkel PA, Niles JL, Mertz LE, et al. Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis and in Microscopic Polyangiitis[J]. Arthritis Care Res (Hoboken), 2021, 73: 1372-1378. doi: 10.1002/acr.24332 [16] Jyssum I, Kared H, Tran TT, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study[J]. Lancet Rheumatol, 2022, 4: e177-e187. doi: 10.1016/S2665-9913(21)00394-5 [17] Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-10 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative[J]. Lancet Rheumatol, 2022, 4: e33-e41. doi: 10.1016/S2665-9913(21)00325-8 -
下载:
点击查看大图
图(2)
计量
- 文章访问数: 190
- HTML全文浏览量: 61
- PDF下载量: 64
- 被引次数: 0
